SecurityHHS / Harte-Hanks, Inc. (416196103)
Institutional Owners46
Institutional Shares28,153,073 - 452.80%
Institutional Value$ 15,225,000 USD

Institutional Stock Ownership and Shareholders

Harte-Hanks, Inc. (NYSE:HHS) has 46 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 28,153,073 shares. Largest shareholders include Wipro Ltd, Dimensional Fund Advisors Lp, VIEX Capital Advisors, LLC, BlackRock Inc., Renaissance Technologies LLC, Credit Suisse Ag/, Vanguard Group Inc, Norges Bank, FMR LLC / Fidelity, and Harte Houston H.

Harte-Hanks, Inc. (NYSE:HHS) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.


File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-02-14 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 228,500 248,000 8.53 245 235 -4.08
2018-02-09 13F-HR SMITH, MOORE & CO. 100,000 100,000 0.00 107 95 -11.21
2018-02-02 13F-HR PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO 19,167 19,167 0.00 21 18 -14.29
2018-02-09 13F-HR Bank of New York Mellon Corp 40,616 41,716 2.71 43 40 -6.98
2018-03-05 SC 13D/A Harte Houston H 660,816 660,816 0.00
2018-02-14 13F-HR Cubist Systematic Strategies, LLC 74,903 74,903 0.00 80 71 -11.25
2018-02-14 13F-HR ROYAL BANK OF CANADA 21,881 21,881 0.00 23 21 -8.70
2018-04-09 13F-HR SHEETS SMITH WEALTH MANAGEMENT 12,635 0 -100.00 12 0 -100.00
2018-02-02 13F-HR GABELLI FUNDS LLC 13,000 13,000 0.00 14 12 -14.29
2018-02-14 13F-HR NORTHERN TRUST CORP 137,777 142,310 3.29 148 135 -8.78
2017-11-14 13F-HR D. E. Shaw & Co., Inc. 181,119 0 -100.00 187 0 -100.00
2018-02-09 13F-HR Virtu Financial LLC 15,830 60,347 281.22 17 57 235.29
2018-02-14 13F-HR MILLENNIUM MANAGEMENT LLC 217,168 91,738 -57.76 232 87 -62.50
2018-02-14 13F-HR PANAGORA ASSET MANAGEMENT INC 14,406 0 -100.00 15 0 -100.00
2018-03-14 13F-HR/A-1 CREDIT SUISSE AG/ 1,317,088 1,317,000 -0.01 1,409 1,250 -11.28
2018-02-14 13F-HR VANGUARD GROUP INC 732,777 1,210,390 65.18 784 1,148 46.43
2018-02-13 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 0 12,600 0 12
2018-04-16 13F-HR Ledyard National Bank 11,485 0 -100.00 11 0 -100.00
2017-11-09 13F-HR TFS CAPITAL LLC 17,419 0 -100.00 18 0 -100.00
2018-02-13 13F-HR GRT CAPITAL PARTNERS L.L.C. 25,664 0 -100.00 26 0 -100.00
2018-02-14 13F-HR BARCLAYS PLC 54 54 0.00 0 0
2018-02-14 13F-HR RAYMOND JAMES & ASSOCIATES 20,000 20,000 0.00 21 19 -9.52
2018-02-09 13F-HR Connor, Clark & Lunn Investment Management Ltd. 286,485 0 -100.00 307 0 -100.00
2018-02-14 13F-HR Invesco Ltd. 143,177 145,221 1.43 153 138 -9.80
2018-02-14 13F-HR MACQUARIE GROUP LTD 74,113 0 -100.00 79 0 -100.00
2018-02-14 13F-HR VIEX Capital Advisors, LLC 2,389,376 2,734,848 14.46 2,557 2,595 1.49
2018-02-13 13F-HR GEODE CAPITAL MANAGEMENT, LLC 253,385 253,385 0.00 271 240 -11.44
2018-02-14 13F-HR MORGAN STANLEY 183,503 179,128 -2.38 197 170 -13.71
2018-02-13 13F-HR Renaissance Technologies LLC 1,674,000 1,751,212 4.61 1,791 1,661 -7.26
2018-02-09 13F-HR BlackRock Inc. 2,108,841 1,910,524 -9.40 2,257 1,813 -19.67
2018-02-12 13F-HR Spark Investment Management LLC 115,200 44,085 -61.73 123 41 -66.67
2018-01-22 13F-HR FIRST MANHATTAN CO 288 288 0.00 0 0
2018-02-01 13F-HR Nationwide Fund Advisors 15,557 0 -100.00 17 0 -100.00
2018-02-14 13F-HR TWO SIGMA INVESTMENTS LLC 26,535 23,820 -10.23 28 23 -17.86
2018-02-14 13F-HR BANK OF AMERICA CORP /DE/ 165 16,390 9,833.33 0 16
2018-02-14 13F-HR PRICE T ROWE ASSOCIATES INC /MD/ 29,750 0 -100.00 32 0 -100.00
2018-02-14 13F-HR TWO SIGMA SECURITIES, LLC 13,171 0 -100.00 14 0 -100.00
2018-02-14 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 10,000 0 -100.00 11 0 -100.00
2018-02-06 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 120,300 120,300 0.00 129 114 -11.63
2017-11-07 13F-HR Cambridge Investment Research Advisors, Inc. 12,000 0 -100.00 12 0 -100.00
2018-02-14 13F-HR Williams Jones & Associates LLC 10,000 0 -100.00 11 0 -100.00
2018-02-14 13F-HR GOLDMAN SACHS GROUP INC 14,102 14,086 -0.11 15 13 -13.33
2018-02-14 13F-HR DEUTSCHE BANK AG\ 0 3,447 0 3
2018-02-14 13F-HR TWO SIGMA ADVISERS, LP 59,429 51,629 -13.12 64 49 -23.44
2018-02-14 13F-HR RBF Capital, LLC 0 32,289 0 31
2018-02-09 SC 13D Wipro Ltd 10,016,586
2018-02-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC 326,692 0 -100.00 350 0 -100.00
2018-02-13 13F-HR JP Morgan Chase & Co 13,189 6,844 -48.11 13 6 -53.85
2018-02-15 SC 13D/A Fondren Management LP 3,680,000 447,290 -87.85
2017-11-13 13F-HR/A-1 NORGES BANK 993,333 968,333 -2.52 1,579 1,498 -5.13
2018-02-09 13F-HR Royce & Associates LLC 653,400 284,200 -56.50 699 270 -61.37
2018-02-09 13F-HR Tower Research Capital LLC (TRC) 25,690 0 -100.00 28 0 -100.00
2018-02-14 13F-HR GUGGENHEIM CAPITAL LLC 16,105 14,317 -11.10 17 14 -17.65
2018-02-14 13F-HR TUDOR INVESTMENT CORP ET AL 21,771 0 -100.00 23 0 -100.00
2018-02-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 0 17,622 0 17
2017-11-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 2,244 0 -100.00 2 0 -100.00
2018-02-13 13F-HR Compagnie Odier SCA 100,000 0 -100.00 107 0 -100.00
2018-02-09 SC 13G/A DIMENSIONAL FUND ADVISORS LP 3,961,916 3,394,875 -14.31
2018-02-14 13F-HR UBS Group AG 17,161 24,395 42.15 18 23 27.78
2018-02-28 13F-HR/A-1 FEDERATED INVESTORS INC /PA/ 6,908 6,908 0.00 7 7 0.00
2018-01-25 13F-HR Foundry Partners, LLC 559,925 536,625 -4.16 599 509 -15.03
2018-04-19 13F-HR Eidelman Virant Capital 2,102,823 208,782 -90.07 1,994 1,911 -4.16
2018-02-14 13F-HR STATE STREET CORP 29,059 24,767 -14.77 32 22 -31.25
2018-02-08 13F-HR WELLS FARGO & COMPANY/MN 73 73 0.00 0 0
2018-02-12 13F-HR FMR LLC / Fidelity 891,055 886,882 -0.47 953 841 -11.75
2018-01-17 13F-HR Cutler Group LP 700 0 -100.00 0 0
2017-11-15 13F-HR/A-1 BRANDES INVESTMENT PARTNERS, LP 70,540 0 -100.00 73 0 -100.00

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 416196103